Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

ChronoScale Holdings Q1 2026 Results: Net Loss of $42.5M, Loss Widens

ChronoScale Holdings Corp reported a significant revenue increase to $41.5 million for the quarter ended August 31, 2026, compared to $16.7 million in the prior year, driven by its cloud computing infrastructure expansion. However, the company realized a net loss of $42.5 million, impacted by a $16.1 million loss from discontinued operations and increased stock-based compensation expenses.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Revenue41.516.7
Net income-42.5-11.2
EPS (diluted, $ a share)$-0.29$-0.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+148.1%
Operating margin-60.0%
Source

10-Q filed with the SEC, NASDAQ: CHRN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ChronoScale Holdings Corp: key numbers

Share price
$9.39Close, Nov 16
Market cap
$1.37B
Shares outstanding
145.64MLatest SEC cover page
Sector
Technology
Industry
General Industrial Machinery & Equipment, NECSIC 3569

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ChronoScale Holdings Corp

All →
4:16 PM ET 8-K
Shareholder Meeting

ChronoScale Holdings Shareholder Meeting

ChronoScale Holdings Corporation held its 2026 Annual Meeting of Stockholders on November 6, 2026. Shareholders elected seven directors, ratified CBIZ CPAs P.C. as the independent auditor for fiscal year 2027, and approved executive compensation and restricted stock awards for non-employee directors.

5:09 PM ET 8-K
Financial Results

ChronoScale Holdings Financial Results

ChronoScale Holdings reported fiscal Q1 2027 revenue of $41.5 million, a 148% year-over-year increase, following its strategic shift toward AI infrastructure. The company completed the divestiture of its legacy Ekso business and secured a major 50 MW AI compute deployment with Microsoft.

Term
Q1 2027

“We believe our strong revenue growth and expanded customer commitments validate the demand we are seeing and our opportunity to grow alongside our customers. Our Microsoft deployment and partnerships with Nutanix and Baseten should position us to serve hyperscale and enterprise AI demand, while the completed Ekso sale is intended to allow us to sharpen our focus on AI infrastructure. With our customer agreements and current deployment schedule supporting an expected $1 billion in annualized revenue run rate by calendar Q3 2027, our priority is disciplined execution and delivering the infrastructure our customers need at scale.”

Cenly Chen, Chief Executive Officer of ChronoScale
5:21 PM ET 8-K
Leadership Change

ChronoScale Holdings Leadership Change

Scott Davis resigned from the Board of Directors of ChronoScale Holdings Corp effective October 3, 2026, following the company's sale of its subsidiary Ekso Bionics, Inc. In connection with his departure, Davis received a lump sum cash payment of $709,500 and 51,626 fully vested restricted stock units as part of a release agreement.

5:28 PM ET 8-K
Divestiture

ChronoScale Holdings Divestiture

ChronoScale Holdings Corporation completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc., to focus resources on its core AI infrastructure business. In connection with the divestiture, Ekso's COO Jason C. Jones was terminated and received a severance package totaling approximately $0.24 million. The company also announced new AI infrastructure contracts expected to drive an annualized revenue run rate of $1 billion by Q3 2027.

5:05 PM ET 8-K
Loan & Debt

ChronoScale Holdings $2M Debt Financing with B. Riley Commercial Capital, LLC

ChronoScale Holdings Corporation's subsidiary entered into an amendment to its secured promissory note with B. Riley Commercial Capital to extend the maturity date of its $2.0 million term loan to November 12, 2026. The amendment also modifies the agreement to allow for the sale of the guarantor, Ekso Bionics, Inc., as a permitted disposition.

Value
$2M
Counterparty
B. Riley Commercial Capital, LLC
Term
through Nov 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.